Project Vice President
Current
Sep 2021 - Present
AeroLeads people directory · profile
Lars-Ole Gerlach Email & Phone Number
Project Vice President, Clinical Drug Development at Novo Nordisk
at
Novo Nordisk
1 work email found
@novonordisk.com
LinkedIn matched
✓ Verified Jun 2026
4 data sources
Profile completeness 100%
Current company
Role
Project Vice President, Clinical Drug Development at Novo Nordisk
Location
Copenhagen, Capital Region Of Denmark, Denmark
Who is Lars-Ole Gerlach? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Lars-Ole Gerlach is listed as Project Vice President, Clinical Drug Development at Novo Nordisk at Novo Nordisk, based in Copenhagen, Capital Region Of Denmark, Denmark. AeroLeads shows a work email signal at novonordisk.com and a matched LinkedIn profile for Lars-Ole Gerlach.
Lars-Ole Gerlach previously worked as Project Vice President at Novo Nordisk and Sr. Director at Novo Nordisk. Lars-Ole Gerlach holds Ph.D., Molecular Pharmacolgy from Københavns Universitet - University Of Copenhagen.
Company email context
Email format at Novo Nordisk
This section adds company-level context without repeating Lars-Ole Gerlach's masked contact details.
{first_initial}{last}@novonordisk.com
86% confidence
AeroLeads found 1 current-domain work email signal for Lars-Ole Gerlach. Compare company email patterns before reaching out.
Profile bio
About Lars-Ole Gerlach
Lars-Ole Gerlach is a Project Vice President, Clinical Drug Development at Novo Nordisk at Novo Nordisk. He possess expertise in corporate law, mergers, acquisitions, foreign investment, contract law and 15 more skills.
Listed skills include Corporate Law, Mergers, Acquisitions, Foreign Investment, and 16 others.
Current workplace
Lars-Ole Gerlach's current company
Company context helps verify the profile and gives searchers a useful next step.
11 roles · 32 years
Lars-Ole Gerlach work experience
A career timeline built from the work history available for this profile.
Sr. Director
- heading up our In vivo pharmacology within diabetes, cardiovascular & kidney disease (team size: 46)- chair of our early innovation bringing new target projects into our research pipeline
Aug 2020 - Aug 2021
Director, Cardiovascular Research
Director of Cardiovascular Research- In vitro and in vivo pharmacology support of cardiovascular disease targets up to non-clinical development. Chairman of CVD 'focus group' - Target identification and evaluation of internal and external opportunities- driving drug discovery innovation and mature early ideas into valid projects.
Aug 2017 - Aug 2020
Director, Diabetes & Cardiovascular Pharmacology
Director of Diabetes & Cardiovascular Pharmacology- In vitro and in vivo pharmacology support of type 2 diabetes and cardiovascular disease targets up to non-clinical development. Type 2 Diabetes target Portfolio Manager- Target discovery and evaluation of internal and external opportunities
Nov 2016 - Aug 2017
Director, Diabetes Biology And Metabolism
Director of Diabetes Biology- In vitro pharmacology support of type 2 diabetes and cardiovascular disease targets up to non-clinical development.
Sep 2015 - Nov 2016
Independent Board Member
Current
Methyldetect
MethylDetect, a small Danish biotech offering ready-to-use kits for detection of aberrant gene methylation. The method has its use within basic research as well as potential biomarkers, e.g. in oncology.
Jan 2017 - Present
Executive Vice President R&D
Epitherapeutics Aps
- EpiTherapeutics was a biotech company focused on drug discovery and development in the field of oncology. First-in-class, selective small molecule inhibitors of the epigenetic class of histone demethylases has been.
- Build efficient & lean R&D organization with majority of activities outsourced yet maintaining full control from office (17 FTE’s in house (15 Ph.D), 8 non-clinical/clinical consultants. Outsourced: 10 FTE chemists (7.
- Facilitated strong communication between disciplines (biology, chemistry, pre-clinical and clinical development)
- Validation of new targets to pipeline
- Pushed small molecule inhibitors from hit identification to clinical candidate nomination and development
- Clear communication of science to Board of Directors, investors as well as in BD relations Main responsibilities & tasks at EpiTherapeutics:
Mar 2011 - Sep 2015
Director Of Pharmacology
- 7TM Pharma was a biotech company focusing on discovery and development of new drugs targeting GPCR receptors. 7TM Pharma’s primary therapeutic area was metabolic diseases, including obesity & diabetes and.
- Forming efficient pharmacology department, ensuring instant and full biology support for the in-house drug discovery programs
- Full pharmacology assessment (in vitro & in vivo) and selection of candidates for pre-clinical nomination and documentation for IND filing
- Established interdisciplinary data-management system
- Performed site-closure (7TM in Hørsholm, CareX in Strasbourg)Main responsibilities & tasks at 7TM Pharma
- Focus on strong interdisciplinary relationship between departments such as Biology, Chemistry, Computational Chemistry, ADME, data management
Apr 2008 - Mar 2011
Head Of In Vitro Pharmacolgy
- Running an efficient in vitro pharmacology department, ensuring instant cellular data for the in-house drug discovery programs (GPCRs)
- Managing department, HR experience
- Assay development
Jan 2005 - Apr 2008
Post Doc.
Post doc. in William F. DeGrado’s lab, Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia.
Jun 2003 - Jun 2004
Student / Research Associate
1994 - 1995
~1 yr
3 education records
Lars-Ole Gerlach education
Ph.D., Molecular Pharmacolgy
Københavns Universitet - University Of Copenhagen
Ms, Biochemistry
Københavns Universitet - University Of Copenhagen
Education record
Kildegaard Gymnasium
FAQ
Frequently asked questions about Lars-Ole Gerlach
Quick answers generated from the profile data available on this page.
What company does Lars-Ole Gerlach work for?
Lars-Ole Gerlach works for Novo Nordisk.
What is Lars-Ole Gerlach's role at Novo Nordisk?
Lars-Ole Gerlach is listed as Project Vice President, Clinical Drug Development at Novo Nordisk at Novo Nordisk.
What is Lars-Ole Gerlach's email address?
AeroLeads has found 1 work email signal at @novonordisk.com for Lars-Ole Gerlach at Novo Nordisk.
Where is Lars-Ole Gerlach based?
Lars-Ole Gerlach is based in Copenhagen, Capital Region Of Denmark, Denmark while working with Novo Nordisk.
What companies has Lars-Ole Gerlach worked for?
Lars-Ole Gerlach has worked for Novo Nordisk, Methyldetect, Epitherapeutics Aps, 7Tm Pharma, and University Of Pennsylvania.
How can I contact Lars-Ole Gerlach?
You can use AeroLeads to view verified contact signals for Lars-Ole Gerlach at Novo Nordisk, including work email, phone, and LinkedIn data when available.
What schools did Lars-Ole Gerlach attend?
Lars-Ole Gerlach holds Ph.D., Molecular Pharmacolgy from Københavns Universitet - University Of Copenhagen.
What skills is Lars-Ole Gerlach known for?
Lars-Ole Gerlach is listed with skills including Corporate Law, Mergers, Acquisitions, Foreign Investment, Contract Law, Corporate Governance, Company Secretarial Work, and Intellectual Property.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial